Hong, Kyung Soo Jang, Jong Geol Hur, Jian Lee, Jong Ho Kim, Hong Nam Lee, Wonhwa Ahn, June Hong 2024-01-12T03:33:27Z 2024-01-12T03:33:27Z 2022-11-21 2020-09 2093-2340 https://pubs.kist.re.kr/handle/201004/76831 There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible. English Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication Article 10.3947/ic.2020.52.3.396 1 Infection and Chemotherapy, v.52, no.3, pp.396 - 402 Infection and Chemotherapy 52 3 396 402 Y scopus kci 2-s2.0-85094979109